Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 Sep 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Panminerva Medica 2020 Sep 21

DOI: 10.23736/S0031-0808.20.04141-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma

Alessandra ROMANO 1, Marco SANTORO 2 , Concetta CONTICELLO 3, Sergio SIRAGUSA 4, Francesco DI RAIMONDO 1, 3, Giovanni MARTINELLI 5, Claudio CERCHIONE 5

1 Dipartimento di Chirurgia e Specialità Medico Chirurgiche, Università degli Studi di Catania, Catania, Italy; 2 Dipartimento di Chirurgia, Stomatologia e Oncologia Sperimentale, Università degli Studi di Palermo, Palermo, Italy; 3 U.O.C. di Ematologia, A.O.U. Policlinico Rodolico San Marco, Catania, Italy; 4 Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, U.O. Ematologia, Università degli Studi di Palermo, Palermo, Italy; 5 Ematologia, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì Cesena, Italy


PDF


Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.


KEY WORDS: Multiple myeloma; Consolidation chemotherapy; Therapy

top of page